Skip to main content

Table 2 The composition of partnerships (non-infectious disease)

From: Biopharma innovation trends during COVID-19 and beyond: an evidence from global partnerships and fundraising activities, 2011-2022

  

Average yearly count (%)a

  

2011-2017

2018-2019 (base group)

2020

2021-2022

Non-Infectious Disease Partnership (N=9,865)

Avg yearly count: 811

Avg yearly count: 790

Avg yearly count: 910

Avg yearly count: 849

Entity Typeb

The ownership of the target company

         

     Public

Involving only publicly owned companies

106

14%

138

18%

181

20%

 

158

19%

     Private

Involving only privately owned companies

156

21%

130

17%

170

19%

 

169

20%

     Public + Private

Involving both publicly and privately owned companies

261

36%

314

40%

349

39%

 

344

41%

     Institution + Public/Private

Involving institutions and other companies

208

28%

200

26%

205

23%

 

176

21%

     Missing

-

(80)

 

(8)

 

(5)

  

(2)

 

Region

The geographical region where the deal took place

         

     Asia-Pacific

-

143

26%

198

33%

251

36%

 

245

36%

     Europe

-

164

30%

147

25%

184

26%

 

158

23%

     North America

-

184

34%

201

34%

205

29%

 

219

32%

     Others

-

55

10%

49

8%

59

8%

 

58

8%

     Missing

-

(265)

 

(195)

 

(211)

  

(169)

 

Therapy Areac

          

Immunology

-

96

13%

92

12%

106

12%

 

90

11%

Oncology

-

326

45%

364

47%

465

51%

 

408

48%

Gastrointestinal

-

75

10%

90

11%

57

6%

***

76

9%

Musculoskeletal Disorders

-

53

7%

58

7%

49

5%

 

48

6%

Metabolic Disorders

-

95

13%

68

9%

63

7%

 

63

7%

Ophthalmology

-

54

7%

60

8%

57

6%

 

49

6%

Cardiovascular

-

58

8%

54

7%

54

6%

 

42

5%

Central Nervous System

-

177

24%

182

23%

160

18%

*

184

22%

Respiratory

-

50

7%

46

6%

51

6%

 

42

5%

Others

-

199

27%

216

28%

228

25%

 

233

28%

Molecule Typec

With a drug/drug candidate of a specific molecule type

         

Gene/Cell Therapy

-

93

13%

140

18%

170

20%

 

131

17%

Protein

-

51

7%

36

5%

41

5%

 

39

5%

Vaccine

-

23

3%

22

3%

18

2%

 

12

2%

Anti-Body

-

128

18%

146

19%

178

21%

 

175

23%

Peptide

-

38

5%

32

4%

36

4%

 

30

4%

Small Molecule

-

362

51%

355

47%

369

43%

 

350

45%

Recombinant

-

42

6%

27

4%

17

2%

 

19

2%

Biologic

-

13

2%

15

2%

17

2%

 

22

3%

Oligonucleotide

-

27

4%

28

4%

36

4%

 

29

4%

  1. a We use the pre-outbreak deals as the baseline group to perform chi-squared tests, examining whether the composition of partnership activities changed during or after the initial global outbreak. The significance of each chi-squared test is denoted by asterisks (*\(P<0.05\), **\(P<0.01\), ***\(P < 0.001\)).
  2. b This is a nominal variable, so the percentages of all subjects add up to 100%.
  3. c This is a set of binary variables that are not mutually exclusive and collectively exhaustive. Since companies have more than one drug in their portfolio, each company could be categorized into several therapy areas or molecule types. To address the multiple comparisons issue, we adjust the significance levels per test through Holm’s step-down extension of the Sidak method, controlling the family-wise error rate at 0.05. The unadjusted significance levels are reported in eTable 4 in the online supplement
Back to article page

Globalization and Health

ISSN: 1744-8603